Hanna D'Souza, Mashael AlKandery, Rishi Mandavia
Autologous biofiller represents a promising addition to the field of regenerative aesthetic medicine, offering encouraging patient outcomes and a good safety profile. This article provides valuable information supporting clinician and patient decision-making, whilst identifying gaps in the literature.
INTRODUCTION: Autologous biofillers are emerging blood-derived regenerative treatments for soft tissue augmentation and regeneration. Despite increasing use, there is limited consensus regarding their definition, preparation, mechanisms, indications, efficacy, longevity, and safety.
AIMS: To systematically review the literature, providing an evidence-based overview of biofillers and informing clinical practice.
METHODS: A systematic review was performed, and studies evaluating autologous blood-derived biofillers for facial soft tissue augmentation were included. Data on definition, preparation, indications, outcomes, longevity, and safety were synthesised narratively.
RESULTS: Twenty studies were included. Biofillers were primarily used for facial rejuvenation, infraorbital restoration, wrinkle reduction, and skin improvement. Clinical outcomes and patient satisfaction were favourable with follow-up up to 10 months, while adverse events were predominantly mild and transient. Heterogeneity in terminology, preparation, and outcome reporting precluded meta-analysis.
CONCLUSIONS: Autologous biofiller represents a promising addition to the field of regenerative aesthetic medicine, offering encouraging patient outcomes and a good safety profile. This article provides valuable information supporting clinician and patient decision-making, whilst identifying gaps in the literature.